Metabolism

Studying Energy Use for Personalized Weight-Loss Treatments

Researchers at the University of Alberta are measuring metabolic adaptation to understand why semaglutide outcomes differ across individuals.

Published November 19, 2026 Read 2 min 347 words Topic Metabolism
Reviewed by: Dr. Michael Teplitsky, MD · November 2026

How Semaglutide Affects Body Weight and Appetite

Semaglutide produces an average weight reduction of 15 percent over 68 weeks, yet patient outcomes show significant variation across clinical settings.

Clinical trials pair weekly doses of the medication with structured diet and exercise interventions.

The medication belongs to a drug class known as glucagon-like peptide-1 (GLP-1) receptor agonists. Semaglutide functions primarily by signaling appetite centers in the brain to decrease hunger and extend sensations of fullness after meals.

Metabolic Adaptation in Personalized Weight-Loss Treatments

Metabolic adaptation occurs when the body lowers its daily energy expenditure beyond the expected reduction caused by tissue loss.

Both fat mass and fat-free mass require calories for basic maintenance, even when a person remains at rest. When body weight decreases, daily caloric requirements drop automatically.

In some people, resting metabolic rate declines more sharply than expected. This adaptive thermogenesis reduces calorie burning during basic tasks like breathing and digestion, which can stall weight reduction and complicates personalized weight-loss treatments.

Current Evidence on Glucagon-Like Peptide-1 Therapy and Energy Use

Existing studies on whether semaglutide directly changes resting energy expenditure remain neutral or inconclusive.

A published literature review by University of Alberta researchers analyzed available trials evaluating how GLP-1 therapies alter daily caloric burning. The team found few studies on resting energy utilization, leaving the underlying metabolic mechanisms unconfirmed.

Individual responses to these medications may instead depend on multiple biological variables. Researchers point to genetics, baseline metabolism, body composition, gut microbiota, age, sex, and concurrent metabolic conditions as potential contributors to the observed differences.

Calorimeter Trials for Personalized Weight-Loss Treatments

A six-month clinical study is tracking how semaglutide alters body composition and active energy utilization in human subjects.

Researchers at the University of Alberta are currently enrolling adults with blood sugar regulation problems, including insulin resistance and type 2 diabetes, who plan to initiate semaglutide.

The protocol uses a specialized whole-room indirect calorimeter that measures gas exchange to calculate calories burned at rest, during light exercise, and following meals. Clarifying these metabolic shifts will help clinicians design targeted dietary and medical strategies for personalized weight-loss treatments.

Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making changes to your health regimen.
Primary source: View original source — referenced for fact-checking; this analysis is independent editorial content.
Found this useful?

Related Articles

Want a clinician to work up your metabolic numbers?

Opt Health runs fasting insulin, A1C, a full lipid panel and 50+ other markers, then builds a treatment plan — GLP-1s included where they're appropriate — with a physician who reviews the data with you directly.

See Opt Health's metabolic program →

Topic updates

Get the weekly metabolic health roundup

Insulin resistance, blood sugar, visceral fat, GLP-1 plateaus, metabolic syndrome, and weight-loss physiology.

No spam. Unsubscribe anytime.

Understand Your Health Better

Our free assessment maps your symptoms to the most relevant guides, tools, and product recommendations.

Take the Free Assessment →

Free · Takes 5 minutes · Instant results